Health in 2025: The 5 medical breakthroughs that gave us hope

Key 2025 medical advances include the first personalised in vivo CRISPR gene edit in a baby with a lethal liver disorder (reducing medication dependence and showing developmental progress by November), mRNA vaccine trials that induced HIV neutralising antibodies, and a genetically modified pig liver that sustained a 71‑year‑old patient for 171 days. Researchers also used living human brain tissue to model early dementia and reported broader potential indications for GLP‑1 weight‑loss drugs, though Novo Nordisk found semaglutide provided no cognitive benefit in dementia; these breakthroughs could materially expand biotech pipelines and licensing/M&A opportunities but require long‑term safety, larger trials and regulatory clearance.

Analysis

Market structure: Near-term winners are platform and enabling players — CRISPR/ gene-editing developers (CRSP, NTLA, EDIT), mRNA platform leaders (MRNA, BNTX) and CDMO/tooling names (TMO, ILMN) that supply vectors, LNPs and sequencing. Lost optionality accrues to specialty incumbents focused on single-indication dementia drugs; Novo Nordisk (NVO) sees a modest negative repricing for a dementia indication but retains strong obesity/diabetes franchise. Pricing power will migrate to scalable platform providers and large vertically integrated CDMOs as demand for trials and manufacturing capacity tightens over quarters.

Risk assessment: Key tail risks include a regulatory pause on in vivo germline or xenotransplantation (probability mid-single digits; impact >30% on small-cap biotech), major adverse events in early human xenotransplant cases, or LNP/raw-material bottlenecks that push program delays. Immediate (days–weeks) implication is elevated share-level IV and sector volatility; short-term (3–9 months) depends on Ph2/Ph3 readouts and FDA/CMS signals; long-term (2–5 years) adoption hinges on reimbursement and durable safety. Hidden dependency: concentrated LNP and high-grade vector supply chains create single-point failure risk for platform revenue growth.

Trade implications: Tactical overweight biotech platforms and CDMOs via 2–3% long positions in MRNA and TMO/ILMN for exposure to mRNA and tooling demand, paired with a 1% tactical hedge short NVO using a 3–6 month 5–10% OTM put spread to limit downside if GLP-1 stigma widens. Use 6–12 month call spreads on CRISPR names (NTLA/CRSP) to express asymmetric upside while selling some IV; reduce cyclicals exposure in favor of defensive healthcare credits if sector volatility rises.

Contrarian angle: Market may underprice the time and capital intensity for xenotransplantation and in vivo editing to become commercial — that argues against overpaying for small-cap pure plays; conversely NVO’s core obesity revenue growth likely offsets the failed dementia signal, so a small contrarian long into weakness (1–2% sized) after any >10% pullback could be profitable. Historical parallel: mRNA hype-cycle (2020–22) showed platform winners consolidate while many small developers fail; hedge positions and size conviction accordingly.

Key Decisions for Investors

• Establish a 2–3% long position in MRNA (Moderna) and a 1–2% position split between TMO (Thermo Fisher) and ILMN (Illumina) over the next 30–90 days to capture durable demand for mRNA vaccines, tooling and CDMO services; target 12–18 month horizon and take profits at +40% or reassess on negative Phase III/regulatory news.
• Implement a pair trade: go long 2% CRSP (CRISPR Therapeutics) or NTLA (Intellia) via 9–12 month call spreads (buy 20% OTM, sell 40% OTM) and short 1% of NVO (Novo Nordisk) via a 3–6 month put spread (buy 5–10% OTM, sell 15–20% OTM) to express platform upside vs limited downside from GLP-1 headline risk; rebalance if NVO moves >10%.
• Buy a 6–12 month protective tail: allocate 0.5–1% to an IG healthcare credit ETF or senior debt of large-cap biotech to hedge systemic biotech drawdowns if a regulatory moratorium occurs (trigger: FDA issues suspension guidance or a major xenotransplant adverse event).
• Monitor specific regulatory catalysts in the next 30–60 days and act on signals: FDA guidance on in vivo gene editing, CMS/Medicare policy statements on GLP‑1 reimbursement, and any transplant regulatory approvals — if any of these turn negative, cut small-cap gene-editing exposure by 50% within 5 trading days.